Active substanceNelarabinNelarabin
Similar drugsTo uncover
  • Atrians
    solution d / infusion 
  • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: nelarabine 5 mg;

    Excipients: sodium chloride 4.5 mg, 0.1 M solution of hydrochloric acid or 0.1 M sodium hydroxide solution to adjust the pH to 5.5-6.5 (average pH 6.0), water for injection to volume 1.0 ml.

    Description:

    Transparent colorless solution without visible mechanical inclusions.

    Pharmacotherapeutic group:Antitumor agent. Antimetabolite
    ATX: & nbsp

    L.01.B.B   Purine analogues

    L.01.B.B.07   Nelarabin

    Pharmacodynamics:

    Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), an analogue of deoxyguanosine. Under the action of adenosine deaminase neelabine rapidly transforms into ara-G, and then, as a result of phosphorylation, it forms its 5-monophosphate and further - araguanosine triphosphate (ara-GTP). As a result of the accumulation of ara-GTP in blast cells in leukemia, it competitively builds into the DNA chain, which causes suppression of DNA synthesis and, consequently, cell death, In vitro it was shown that T cells are more sensitive to the cytotoxic effects of nelarabine compared to B cells.

    Pharmacokinetics:
    Suction

    The maximum concentration (Cmax) ara-G in the blood plasma is reached after the end of infusion of nelarabine and on average higher than Cmax nelarabine, which involves a rapid and intensive transformation of the prodrug into a drug. After a two-hour infusion of non-larabine in a dose of 1500 mg / m2 adult patients mean Cmax nelarabine and ara-G were 13.9 μmol and 115 μmol, respectively. Average values ​​of areas under the curve "concentration-time" (AUC) nelarabine and ara-G were 13.5 μmol / h and 571 μmol / h, respectively, after an infusion of 1500 mg / m2. Intracellular Cmax for ara-GTP is achieved through 3-25 hours for the first day of the course treatment. The mean intracellular values ​​of Stach and AUC ara-GTP were 95.6 μmol and 2214 μmol / h for this dose.

    Binding to blood plasma proteins and distribution

    Nelarabine and ara-G are characterized by a large volume of distribution. The volume of distribution in the equilibrium state (Vss) in adults and children was, respectively, 115 l / m2 and 89.4 l / m2. The apparent volume of the apra-F distribution (Vss/ F) is 44.8 l / m2 and 32.1 l / m2 in adults and children, respectively.

    The binding of nelarabine and ara-G to plasma proteins is insignificant and is less than 25%, for both components it does not depend on the concentration in the range up to 600 μmol.

    There was no cumulation of either nelarabine or ara-G, including under the "1, 3, 5 days ".

    Intracellular concentrations of ara-GTP in lymphoblasts were determined for a long period after infusion of non-larabine. Cumulation of ara-GTP within cells with repeated infusions of nelarabine according to the scheme "1, 3, 5" with increasing values ​​of Cmax and AUC (O-t) on the third day of treatment by 50% and 30%, respectively, compared with the same indicators for the first day of the course.

    Metabolism

    The main pathway of biotransformation of non-larabine is O-demethylation with adenosine deaminase with the formation of ara-G, further metabolized to guanine. Besides, neelabine partially hydrolyzed to methylguanine, which then undergoes O-demethylation to form guanine. The next step is N- deamination of guanine with the formation of xanthine and its oxidation to uric acid.

    Excretion

    Nelarabine and ara-G are rapidly excreted from the blood plasma, the half-life is 30 minutes and 3 hours after the infusion at a dose of 1500 mg / m2. The average clearance of non-larabine when administered at doses from 104 to 2900 mg / m2 in adults and children was, respectively, 138 l / h / m and 125 l / h / m per day 1. Apparent ground clearance ara-G comparable in both age groups and is 9.5 l / h / m2 in adults and 10.8 l / h / m2 in children per day 1.

    Nelarabine and ara-G are excreted partly by the kidneys. The average number excreted by the kidneys is 5.3% and 23.2% of the administered dose for neuralabine and ara-G, 24 hours after the infusion of non-larabine on day 1. The renal clearance is on average 16.4 l / h for nelarabine and 4.9 l / h for ara-G.

    Special patient groups

    Children

    The main pharmacokinetic parameters in children are similar to those in adults.

    Elderly

    There are no differences in the basic pharmacokinetic parameters.

    Patients with impaired renal function

    Clinical studies included patients with a creatinine clearance above 80 mL / min, with impairment. renal function weak (creatinine clearance 50-80 ml / min) and moderate (creatinine clearance less than 50 ml / min) degrees. The average apparent clearance of ara-G is 7% lower in patients with moderate renal impairment. There were no differences in efficacy and safety of the drug.

    Patients with impaired hepatic function:

    No data

    Clinical efficacy and safety

    Nelarabin showed clinical efficacy in the recommended "adult" and "infant" dose in patients in two independent clinical trials - CALGB 19801 and COG P9673. In adults with acute T-cell lymphoblastic leukemia or T-lymphoma, after two or more induction courses, monotherapy with non-larabin resulted in complete remission (PR) in 18% of cases (95% CI: 6% -37%) with a total remission period of 15 to 195+ weeks; Survival after 1 year was 29%, which confirms the clinical efficacy of the drug in this group of patients who had previously undergone intensive treatment. Close indicators were obtained in children and patients no older than 21 years with recurrent or refractory acute T-cell lymphoblastic leukemia or T-lymphoma after two or more induction courses (group 02): monotherapy with non-larabine caused complete remission in 13% of cases (CI 95%: 4% -27%) with a duration of PR of 4.7 to 36.4 weeks; Survival after 1 year was 14%.

    In some patients, after two or more courses of ineffective induction, during the period of complete remission achieved with ionotherapy with nelarabine, stem cell transplantation was performed. At the time of transplantation, the duration of complete remission was 1.6 to 9.3 weeks in children and 6.3 to 195.4 + weeks. adults. In the study PGAA2001 data on the restoration of hematological parameters were obtained in 21 of 27 patients,which after the therapy with non-larabine, transplantation of hematopoietic stem cells was performed. Of these, in 20 patients (95%), neutrophil recovery was confirmed. In the study PGAA2002 data on the restoration of hematological parameters were obtained in 6 of 7 patients who underwent transplantation of hematopoietic stem cells after treatment with non-larabin. In 3 of them (50%) there was a recovery of the level of neutrophils.

    Interestingly, in refractory patients, after an ineffective induction course, treatment with non-larabine provided an impressive frequency of complete remission - 18% in adults and children after two or more previous courses of induction and 44% in children after one previous course of induction. In addition to patients who achieved complete remission, in one adult patient and in three children with refractory course of the disease, complete remission was achieved with the optional normalization of hematologic parameters.

    Indications:- T-cell acute lymphoblastic leukemia

    - T-cell lymphoblastic lymphoma

    Contraindications:

    Hypersensitivity to any of the components of the drug.

    Carefully:
    Pregnancy and lactation:No data.
    Dosing and Administration:
    The course of treatment with malarabine can be performed only by a specialist who has experience in the use of antitumor drugs.

    The drug is intended for intravenous infusion in undiluted form.

    Adults (16 years and over)

    The recommended dose is 1500 mg / m2, intravenously, for 2 hours, on days 1,3 and 5, every 21 day.

    Children (up to 16 years)

    The recommended dose is 650 mg / m2, intravenously, for 1 hour, consistently 5 days (days 1 - 5), every 21 days.

    Modification of the dose

    The use of non-larabine should be discontinued at the first sign of neurotoxicity of the second degree of severity and higher according to the criteria of toxicity of the National Cancer Institute. Increasing the intervals between dosing can be considered as an alternative for the development of other toxic manifestations, including hematologic toxicity.

    Patients with impaired renal function: there is insufficient data to formulate specific recommendations for correcting the dosage regimen when creatinine clearance is less than 50 ml / min. Given the partial excretion of the kidneys, careful monitoring of the clinical condition of the patient is required.

    Patients with impaired hepatic function: insufficient data are available to formulate specific recommendations for correcting the dosage regimen.

    Side effects:

    The safety of nelarabine was assessed for the general population of patients enrolled in clinical trials. A general safety assessment was conducted for 103 adults and 84 children enrolled in controlled clinical trials. The most common adverse events: fatigue, gastrointestinal disorders, hemopoiesis disorders, respiratory system disorders and fever. Neurotoxicity is dose dependent. The adverse events presented below are listed in accordance with organ and organ damage and frequency of occurrence. Frequency of occurrence is defined as follows: highly often (1/10), often (≥1 / 100 and <1/10), notoften (≥1 / 1,000 and <1/100), rarely (≥ 1/10 000 and <1/1 000), rarely (<1/10 LLC, including individual cases). Frequency categories were formed on the basis of clinical studies of the drug.

    Infections and invasions:

    Highly often: infections, including sepsis, bacteremia, pneumonia, fungal infections. Haveseparate messages about development of fatal spurstunistic infections.

    Registered one casedevelopment tea in an adult progressing multifocal leukoencephalopathy, confirmed by biopsy.

    Neoplasms (benign and Malignant, including cysts and polyps) in adults

    Often: tumor lysis syndrome.

    From the side of metabolism

    Highly often: hypokatemia (children). Often: hypokatiyemia (adults), hypocalcemia, hypomaghypoglycaemia (dety), anorexia (adults), increase in concentration creatinine in the blood.

    From the side of the blood, the system is bleedingrhenia and lymphatic system:

    Highly often: febrile neutropenia (adults), neutropenia, leukopenia (children), thrombosiscytopenia, anemia. Often: febrile neutropenia (children), leukopenia (adultsthirds).

    From the side of the cardiovascular systemadult themes:

    Often: reduction of arterial pressure.

    From the respiratory, thoracic and mediastinal (adults):

    Highly often: dyspnea, cough. Often: pleural effusion, whistlingrales.

    From the gastrointestinal side tract

    Often:

    adults: diarrhea, nausea, vomiting, constipation.

    Often: adults: stomatitis, abdominal pain; children: diarrhea, stomatitis, nausea, vomiting, constipation.

    From the liver and biliary tract

    Often: children: an increase in the activity of "liver" transaminases.

    Often: hyperbilirubinemia, adultBare: increase in concentration aspartate-

    aminotransferase.

    From the musculoskeletal system and connective tissue

    Often:

    adults: myalgia.

    Often: adults: muscular weakness, back pain, arthralgia, pain in the limbs;

    children: arthralgia, pain in the extremities.

    From the body as a whole

    Highly often. adults: edemas, peripheryedema, increased body temperature, pain, fatigue, asthenia.

    Often: adults: breaking hikeki,

    children: feverbody tours, pain, fatigueand asthenia.

    From the side of the organs of vision in adults

    Often: decreased visual acuity.

    From the nervous system and the psyche

    Highly often:

    adults: dizziness, decreased sensitivity, paresthesia, drowsiness; peripheral neurologic disorders (motor and sensory), headache; children: peripheral neurological disorders (motor and sensory), headache.

    Often: adults: confusionnania, amnesia, perversion taste, violation of control balance of the body, cloudedvision, convulsions (including convulsions, epipeptic status, large epileptic seizure), ataxia, tremor;

    children: drowsiness, decrease sensitivity, paresthesia;

    convulsions (including convulsions)these epileptic status, large epileptic attack), tremor, ataxia, confusion of consciousness.

    Highly rarely: demyelination, ascendingperipheral neuropathy, similar in manifestations with Guillain-Barre syndrome (Guillain-Barre). Registration formOne case is fatalth epileptic status of patient of child age

    Undesirable phenomena presented below were formed on the basis of postgistrational observation.

    Disorders from the side of the skeletal- rhabdomyolysis (acute necrosis of skeletal muscles), an increase in the level of creatine phosphokinase in the blood.

    Overdose:
    There is no specific antidote.

    Symptoms and signs:

    Presumably, an overdose of the drug is accompanied by symptoms of severe neurotoxicity, myelosuppression and can have fatal consequences.

    Treatment

    Symptomatic therapy. Hemodialysis is not effective.

    Interaction:
    30-minute infusion of 30 mg / m2 fludarabine 4 hours before the administration of neurabine did not affect the pharmacokinetics of nelarabine, ara-G and ara-GTP.

    Nelarabine and ara-G are not substrates or inhibitors of glycoprotein-P and do not inhibit the activity of cytochromes P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4). In addition, the binding of nelarabine and ara-G to human plasma proteins is weak (less than 25%) and does not depend on concentration. Thus, this mechanism can not sufficiently provide possible drug interactions.

    Pentostatin (deoxycoformycin) is a potent inhibitor of adenosine deaminase (ADA). In studies of cytotoxicity in vitro an increase in the concentration of nelarabine, suppressing cell growth (IC50), in proportion to the increase in the concentration of inhibitors of ADA. The studied inhibitors of ADA did not affect the value IC50 ara-G. According to the research results in vitro using other inhibitors of ADA, the efficacy of nelarabine may decrease in the presence of pentostatin; Simultaneous use of non-larabine and adenosine deaminase inhibitors is not recommended.

    Special instructions:

    Nelarabine is an active cytostatic.The use of the drug is possible only under the supervision of a doctor with experience in working with cytostatics.

    Strict monitoring of the patient's condition is necessary because of the risk of developing neurotoxic phenomena. The list of undesirable reactions associated with the manifestation of neurotoxicity is given in the section "Undesirable reactions" of this instruction.

    Neurotoxicity is a dose-enhancing factor. The use of non-larabine should be discontinued at the first sign of neurotoxicity of the second severity level and above the criteria of toxicity of the National Cancer Institute.

    The risk group for developing neurotoxic manifestations can include patients who have received or previously received chemotherapy intrathecally or craniospinal irradiation.

    There is insufficient data on the use of nelarabine in elderly patients (65 years and older). It is possible that patients 65 years of age and older are also at increased risk of developing neurotoxic effects of the drug.

    In patients at risk of tumor lysis, intravenous rehydration is recommended in accordance with accepted standards to prevent hyperuricemia. Consider the need for simultaneous administration of allopurinol.

    It is not recommended immunization with live vaccines in patients with a reduced immune status because of the danger of infection.

    Constant monitoring of the blood count, including platelet count, is required, due to possible hematologic toxicity of the drug (see also "Undesirable reactions" section)

    Nelarabine has a genotoxic effect on mammalian cells.

    Women and men during therapy with non-larabine and at least 3 months after it should use reliable methods of contraception.

    Effect on the ability to drive transp. cf. and fur:

    Because the neelabine causes drowsiness that lasts for several days after the infusion, the overall clinical condition of the patient and the possible development of adverse events should be taken into account when assessing the ability to drive and work with machinery requiring rapid reaction.

    Form release / dosage:

    Solution for infusions 5 mg / ml.

    Packaging:50 ml in bottles of glass type I, sealed with a cork made of bromobutyl rubber and coated with an aluminum cap with a snap-off plastic lid.

    By 6 vials with instructions for use in a pack of cardboard.

    Storage conditions:

    At a temperature of no higher than 30 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-009514/08
    Date of registration:28.11.2008 / 11.07.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:GlaxoSmithKline Trading, ZAO GlaxoSmithKline Trading, ZAO Russia
    Manufacturer: & nbsp
    Representation: & nbspGlaxoSmithKline Trading, ZAOGlaxoSmithKline Trading, ZAO
    Information update date: & nbsp04.10.2017
    Illustrated instructions
      Instructions
      Up